The solid–state form of active pharmaceutical ingredients (APIs) governs critical attributes that determine their stability, manufacturability and therapeutic performance. Variations in molecular arrangement within the lattice can lead to contrasting physicochemical and mechanical properties, creating both challenges and opportunities in pharmaceutical development. This thesis employs crystal engineering as a strategy to address the relationship between supramolecular structure with the mechanical response and chemical stability challenges observed in pharmaceutical solids. In the first part of the thesis, a systematic analysis of the structure–mechanical property relationship of polymorphic forms of Mavacamten API revealed the role of interaction topology in influencing the macroscopic mechanical properties. Multiple polymorphs were isolated and characterized. Nanoindentation was employed to quantify hardness and elastic modulus. Correlation of the nanoindentation results with the crystal structure demonstrated that the hydrogen–bonding motifs, packing anisotropy, and the interlayer molecular network may influence the lattice stiffness and the deformation behaviour. The anisotropic mechanical response of crystalline pharmaceutical API polymorphs provides insight into processability and tabletability. Extending beyond the mechanical properties, the second part of the thesis addresses a critical challenge in pharmaceutical stability: the formation of N–nitrosamine impurities in marketable APIs. Strategies for mitigating this challenge are investigated through crystal engineering. Nintedanib and Zanubrutinib APIs containing a secondary amine functional group were employed as model systems. The mechanistic origins and pathways of nitrosation and oxidative degradation are explored by correlating the molecular functionality and conditions. The crystal engineering strategy to design multi–component forms, including co-crystals and salt with the selected complementary excipients, which are reported to exhibit nitrosamine scavenging ability, is employed to mitigate the challenge. The experimental nitrosation tests and oxidative stress tests on the engineered systems demonstrate that the modification of the crystal environment can regulate the accessibility and reactivity of chemically reactive sites, thereby reducing susceptibility to degradation pathways under the investigated experimental conditions without altering the molecular identity of API. By integrating investigations of mechanical behaviour and chemical stability analysis in marketable APIs, this thesis establishes a structure–property–stability framework for pharmaceutical solids. The findings highlight the potential of crystal engineering for optimizing the mechanical properties and manufacturability. It can be applied as a powerful tool in impurity mitigation and stability enhancement, thereby contributing to the rational solid form selection and industrial formulations. Although the two case studies address different pharmaceutical challenges, both demonstrate how crystal engineering can be used to manipulate solid-state organization to control functional properties of pharmaceutical materials.
La forma solida degli ingredienti farmaceutici attivi (API) determina caratteristiche cruciali che ne influenzano la stabilità, la lavorabilità e l'efficacia terapeutica. Differenze nell'organizzazione molecolare all'interno del reticolo possono portare a proprietà fisico-chimiche e meccaniche molto diverse, creando sia sfide sia opportunità nello sviluppo farmaceutico. Questa tesi utilizza l'ingegneria dei cristalli come strategia per affrontare la relazione tra struttura supramolecolare e le problematiche legate alla risposta meccanica e alla stabilità chimica osservate nei solidi farmaceutici. Nella prima parte della tesi, un'analisi sistematica della relazione struttura–proprietà meccaniche delle forme polimorfiche dell'API Mavacamten ha rivelato il ruolo della topologia delle interazioni nell'influenzare le proprietà meccaniche macroscopiche. Sono stati isolati e caratterizzati diversi polimorfi. La nanoindentazione è stata impiegata per quantificare la durezza e il modulo elastico. La correlazione dei risultati della nanoindentazione con la struttura cristallina ha dimostrato che i modelli di legami a idrogeno, l'anisotropia dell'impaccamento e la rete molecolare interstrato possono influenzare la rigidità del reticolo e il comportamento alla deformazione. La risposta meccanica anisotropa dei polimorfi cristallini degli API farmaceutici fornisce indicazioni sulla processabilità e sulla comprimibilità. Estendendosi oltre le proprietà meccaniche, la seconda parte della tesi affronta una sfida critica nella stabilità dei farmaci: la formazione di impurità N–nitrosamine negli API commercializzabili. Le strategie per mitigare questa sfida sono investigate attraverso l'ingegneria cristallina. Gli API Nintedanib e Zanubrutinib contenenti un gruppo funzionale ammina secondaria sono stati impiegati come sistemi modello. Le origini meccanicistiche e i percorsi della nitrosazione e della degradazione ossidativa sono esplorati correlando la funzionalità molecolare e le condizioni. La strategia dell'ingegneria cristallina per progettare forme multi-componente, inclusi co-cristalli e sali con eccipienti complementari selezionati, che sono riportati come capaci di catturare le nitrosamine, è impiegata per mitigare la sfida. I test sperimentali di nitrosazione e di stress ossidativo sui sistemi ingegnerizzati dimostrano che la modifica dell'ambiente cristallino può regolare l'accessibilità e la reattività dei siti chimicamente reattivi, riducendo così la suscettibilità ai percorsi di degradazione nelle condizioni sperimentali investigate senza alterare l'identità molecolare dell'API. Integrando studi sul comportamento meccanico e analisi della stabilità chimica negli API commercializzabili, questa tesi stabilisce un quadro struttura–proprietà–stabilità per i solidi farmaceutici. I risultati mettono in evidenza il potenziale dell'ingegneria cristallina per ottimizzare le proprietà meccaniche e la producibilità. Può essere applicata come strumento potente per ridurre le impurità e migliorare la stabilità, contribuendo così alla selezione razionale delle forme solide e delle formulazioni industriali. Sebbene i due casi studio affrontino sfide farmaceutiche diverse, entrambi dimostrano come l'ingegneria cristallina possa essere utilizzata per manipolare l'organizzazione allo stato solido e controllare le proprietà funzionali dei materiali farmaceutici.
Investigating mechanical properties and nitrosamine mitigation strategies in pharmaceutical solids through crystal engineering
SURESH, AJAY
2026
Abstract
The solid–state form of active pharmaceutical ingredients (APIs) governs critical attributes that determine their stability, manufacturability and therapeutic performance. Variations in molecular arrangement within the lattice can lead to contrasting physicochemical and mechanical properties, creating both challenges and opportunities in pharmaceutical development. This thesis employs crystal engineering as a strategy to address the relationship between supramolecular structure with the mechanical response and chemical stability challenges observed in pharmaceutical solids. In the first part of the thesis, a systematic analysis of the structure–mechanical property relationship of polymorphic forms of Mavacamten API revealed the role of interaction topology in influencing the macroscopic mechanical properties. Multiple polymorphs were isolated and characterized. Nanoindentation was employed to quantify hardness and elastic modulus. Correlation of the nanoindentation results with the crystal structure demonstrated that the hydrogen–bonding motifs, packing anisotropy, and the interlayer molecular network may influence the lattice stiffness and the deformation behaviour. The anisotropic mechanical response of crystalline pharmaceutical API polymorphs provides insight into processability and tabletability. Extending beyond the mechanical properties, the second part of the thesis addresses a critical challenge in pharmaceutical stability: the formation of N–nitrosamine impurities in marketable APIs. Strategies for mitigating this challenge are investigated through crystal engineering. Nintedanib and Zanubrutinib APIs containing a secondary amine functional group were employed as model systems. The mechanistic origins and pathways of nitrosation and oxidative degradation are explored by correlating the molecular functionality and conditions. The crystal engineering strategy to design multi–component forms, including co-crystals and salt with the selected complementary excipients, which are reported to exhibit nitrosamine scavenging ability, is employed to mitigate the challenge. The experimental nitrosation tests and oxidative stress tests on the engineered systems demonstrate that the modification of the crystal environment can regulate the accessibility and reactivity of chemically reactive sites, thereby reducing susceptibility to degradation pathways under the investigated experimental conditions without altering the molecular identity of API. By integrating investigations of mechanical behaviour and chemical stability analysis in marketable APIs, this thesis establishes a structure–property–stability framework for pharmaceutical solids. The findings highlight the potential of crystal engineering for optimizing the mechanical properties and manufacturability. It can be applied as a powerful tool in impurity mitigation and stability enhancement, thereby contributing to the rational solid form selection and industrial formulations. Although the two case studies address different pharmaceutical challenges, both demonstrate how crystal engineering can be used to manipulate solid-state organization to control functional properties of pharmaceutical materials.| File | Dimensione | Formato | |
|---|---|---|---|
|
2026_7_Suresh.pdf
non disponibili
Licenza:
Tutti i diritti riservati
Dimensione
7.38 MB
Formato
Adobe PDF
|
7.38 MB | Adobe PDF |
I documenti in UNITESI sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/20.500.14242/385226
URN:NBN:IT:POLIMI-385226